1 results for "Pharmacy "
The purpose of this study is to see if Filgotnib, oral JAK-1 inhibitor, is effective and safe in treating people with moderate to severe Crohn’s Disease, which is an inflammatory disease of the gastrointestinal tract (digestive tract).
This is a randomized study in which the patient will be assigned to treatment 1 or treatment 2 of the study medication or a placebo. This is also a blinded study which means that the physician (principal investigator), staff, or pharmacy will not know which treatment the patient is assigned to. If by week 10 the patient does not respond to their assigned treatment he/she will have the option to be randomized into the long term extension study in one of the study medication treatments.